XML 105 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1
Significant agreements - Genentech Collaboration Agreement (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Feb. 21, 2020
USD ($)
item
Dec. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Oct. 31, 2021
USD ($)
Dec. 31, 2024
USD ($)
item
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Significant agreements.                
Deferred revenue   $ 61,873     $ 101,658 $ 135,194 $ 61,873  
Collaboration revenue         35,275 26,976 14,463  
Genentech                
Significant agreements.                
Number of potential development candidates | item 4              
Upfront cash payment $ 30,000              
Number of immuno oncology targets | item 2              
Additional number of immuno oncology targets | item 2              
Expansion fee $ 10,000              
Milestone payments, receivable               $ 2,000
Transaction price 31,000       33,000     $ 33,000
Deferred revenue   39,308     14,038 29,104 39,308  
Collaboration revenue         $ 14,840 11,969 3,565  
Genentech | Royalty                
Significant agreements.                
Number of years over which royalty is payable         10 years      
Genentech | Maximum                
Significant agreements.                
Milestone payments, receivable 200,000              
Genentech | Development milestone | Maximum                
Significant agreements.                
Milestone payments, receivable 65,000              
Genentech | Regulatory milestone | Maximum                
Significant agreements.                
Milestone payments, receivable $ 135,000              
Genentech | Collaboration Program 1 Performance Obligation                
Significant agreements.                
Transaction price         $ 4,019      
Genentech | Collaboration Program 1 Performance Obligation | Maximum                
Significant agreements.                
Period over which performance obligations will be performed         2 years      
Material rights exercise period         5 years      
Genentech | Collaboration Program 1 Performance Obligation | Minimum                
Significant agreements.                
Period over which performance obligations will be performed         1 year      
Material rights exercise period         4 years      
Genentech | Collaboration Program 2 Performance Obligation                
Significant agreements.                
Transaction price         $ 8,037      
Genentech | Specified Targeting Arm Material Right Arm Program One                
Significant agreements.                
Number of initial collaboration programs exercised | item 1              
Option fee for development and exploitation rights $ 1,000              
Milestone payments, receivable $ 1,000              
Transaction price         $ 352      
Genentech | Two material rights associated with the LSR Go Option for Collaboration Programs One And Two                
Significant agreements.                
Number of collaboration programs | item 2       2      
Number of expansion option collaboration programs | item         2      
Transaction price         $ 12,400      
Genentech | Material rights associated with limited substitution rights                
Significant agreements.                
Transaction price         1,187      
Deferred revenue   700         700  
Genentech | Two material rights for Expansion Options                
Significant agreements.                
Number of expansion option collaboration programs | item 2              
Transaction price         7,005      
Genentech | Collaboration Program One and Two Performance Obligation | Maximum                
Significant agreements.                
Regulatory, and initial commercialization milestones, payments receivable $ 200,000              
Genentech | Material rights associated with the LSR Go Option for Collaboration Programs One                
Significant agreements.                
Deferred revenue           $ 6,000    
Genentech | Collaboration Program 3 Performance Obligation                
Significant agreements.                
Expansion fee     $ 10,000 $ 10,000        
Milestone payments, receivable       1,000        
Transaction price       11,000        
Material rights       $ 3,500        
Amount of estimate of variable consideration   $ 2,000            
Collaboration revenue     8,400   10,400      
Revenue recognized         $ 7,500      
Genentech | Collaboration Program 3 Performance Obligation | Maximum                
Significant agreements.                
Period over which performance obligations will be performed   3 years            
Genentech | Collaboration Program 3 Performance Obligation | Minimum                
Significant agreements.                
Period over which performance obligations will be performed   2 years            
Genentech | Collaboration Program 4 Performance Obligation                
Significant agreements.                
Expansion fee     10,000          
Deferred revenue   $ 100         100  
Material rights     3,500          
Collaboration revenue     $ 5,300          
Genentech | Material rights associated with the LSR Go Option for Collaboration Programs Three                
Significant agreements.                
Deferred revenue   7,400         7,400  
Genentech | Material rights associated with the LSR Go Option for Collaboration Programs Four                
Significant agreements.                
Deferred revenue   $ 7,400         $ 7,400